At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Orange based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
CFO and EVP Corporate Development of Evolus
Lauren Silvernail is the Chief Financial Officer and Executive Vice President, Corporate Development at Evolus.
Follow Lauren Silvernail:
About Evolus: Evolus medical aesthetics focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments.
Sr. Vice President & Chief Financial Officer of Beckman Coulter
Follow Knud Mueller:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Chief Financial Officer of GW Pharmaceuticals
Scott Giacobello brings 25 years of finance and operational experience to GW Pharmaceuticals.He is an accomplished executive who most recently and until its acquisition by Allergan, Inc. in late 2016, served as Chief Financial Officer for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as Vice President of Finance for Global Research & Development. While at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. Scott’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a Certified Public Accountant.
Follow Scott Giacobello:
About GW Pharmaceuticals: GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
Interim Chief Financial Officer of Mustang Bio
Follow David Horin:
About Chord Advisors, Mustang Bio: Mustang Bio is a clinical-stage biopharmaceutical company .
Paul J. Lytle
Chief Financial Officer of Avid Biosciences
Paul J. Lytle has served as Chief Financial Officer since August 2002 and has over 17 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a B.S. in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.
Follow Paul J. Lytle:
About Avid Biosciences: Avid Bioservices’ expansion will double existing capacity to service both a $40m backlog and its owner Peregrine.
Co-Founder, Vice President, CFO of Harbor MedTech
Follow Jim Jungwirth:
About Harbor MedTech: Harbor MedTech develops and commercializes tissue regeneration products for chronic wounds, hernia and joint repair, and more.